BACKGROUND: We describe the short- and long-term outcomes for PDAC patients after tailored mesopancreas dissection using supracolic artery-first approach followed by adjuvant therapy. METHODS: This study analyzed 233 consecutive patients who underwent artery-first pancreaticoduodenectomy for PDAC. Dissection extent for the superior mesenteric artery (SMA) was categorized into three levels: level 2 (LV2) including regional lymph nodes, level 3 (LV3) with hemicircumferential nerve plexus dissection, and extended-level 3 (E-LV3) including borderline resectable cases for the SMA. All clinical, pathological, and survival outcomes were reviewed. RESULTS: LV2/3/E-LV3 dissection was performed in 77/115/41 patients. The short-term outcomes were similar among groups without mortality. Although postoperative diarrhea requiring opioids was significantly more frequent in the E-LV3 group (76%) than other groups (vs. LV2 (21%), P < .0001; vs. LV3 (34%), P < .0001; LV2 vs. LV3, P = 0.20), most cases of diarrhea were well controlled. Adjuvant chemotherapy was introduced similarly among groups (LV2, 76%; LV3, 81%; E-LV3, 88%, P = 0.29). The 3- and 5-year overall survival rates in the LV2/3/E-LV3 groups were 42/33/42% and 27/22/26%, respectively, showing no significant difference among groups. DISCUSSION: Our tailored dissection and preemptive use of opioid antidiarrheal effectively prevents intractable diarrhea, increasing the success of adjuvant chemotherapy.
BACKGROUND: We describe the short- and long-term outcomes for PDAC patients after tailored mesopancreas dissection using supracolic artery-first approach followed by adjuvant therapy. METHODS: This study analyzed 233 consecutive patients who underwent artery-first pancreaticoduodenectomy for PDAC. Dissection extent for the superior mesenteric artery (SMA) was categorized into three levels: level 2 (LV2) including regional lymph nodes, level 3 (LV3) with hemicircumferential nerve plexus dissection, and extended-level 3 (E-LV3) including borderline resectable cases for the SMA. All clinical, pathological, and survival outcomes were reviewed. RESULTS: LV2/3/E-LV3 dissection was performed in 77/115/41 patients. The short-term outcomes were similar among groups without mortality. Although postoperative diarrhea requiring opioids was significantly more frequent in the E-LV3 group (76%) than other groups (vs. LV2 (21%), P < .0001; vs. LV3 (34%), P < .0001; LV2 vs. LV3, P = 0.20), most cases of diarrhea were well controlled. Adjuvant chemotherapy was introduced similarly among groups (LV2, 76%; LV3, 81%; E-LV3, 88%, P = 0.29). The 3- and 5-year overall survival rates in the LV2/3/E-LV3 groups were 42/33/42% and 27/22/26%, respectively, showing no significant difference among groups. DISCUSSION: Our tailored dissection and preemptive use of opioid antidiarrheal effectively prevents intractable diarrhea, increasing the success of adjuvant chemotherapy.
Entities:
Keywords:
Adjuvant therapy; Artery first; Diarrhea; Pancreaticoduodenectomy; Superior mesenteric artery
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Moritz N Wente; Claudio Bassi; Christos Dervenis; Abe Fingerhut; Dirk J Gouma; Jakob R Izbicki; John P Neoptolemos; Robert T Padbury; Michael G Sarr; L William Traverso; Charles J Yeo; Markus W Büchler Journal: Surgery Date: 2007-11 Impact factor: 3.982
Authors: C J Yeo; J L Cameron; T A Sohn; J Coleman; P K Sauter; R H Hruban; H A Pitt; K D Lillemoe Journal: Ann Surg Date: 1999-05 Impact factor: 12.969
Authors: Michael B Farnell; Randall K Pearson; Michael G Sarr; Eugene P DiMagno; Lawrence J Burgart; Tamela R Dahl; Nathan Foster; Daniel J Sargent Journal: Surgery Date: 2005-10 Impact factor: 3.982
Authors: David K Chang; Amber L Johns; Neil D Merrett; Anthony J Gill; Emily K Colvin; Christopher J Scarlett; Nam Q Nguyen; Rupert W L Leong; Peter H Cosman; Mark I Kelly; Robert L Sutherland; Susan M Henshall; James G Kench; Andrew V Biankin Journal: J Clin Oncol Date: 2009-04-27 Impact factor: 44.544
Authors: Tom C Nguyen; Taylor A Sohn; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; JoAnn Coleman; Patricia K Sauter; Ross A Abrams; Ralph H Hruban; Charles J Yeo Journal: J Gastrointest Surg Date: 2003-01 Impact factor: 3.452
Authors: Min Young Park; Woohyung Lee; Jaewoo Kwon; Ki Byung Song; Dae Wook Hwang; Jae Hoon Lee; Song Cheol Kim Journal: Ann Hepatobiliary Pancreat Surg Date: 2021-08-31
Authors: Eduardo de Souza M Fernandes; Oliver Strobel; Camila Girão; Jose Maria A Moraes-Junior; Orlando Jorge M Torres Journal: Langenbecks Arch Surg Date: 2021-06-12 Impact factor: 3.445
Authors: Lan Thi Nguyen; Hung Van Nguyen; Dang Hai Do; Khiem Thanh Nguyen; Anh Tuan Do; Ha Hoang Pham; Chinh Duc Nguyen Journal: Ann Med Surg (Lond) Date: 2021-05-01
Authors: M Franceschilli; D Vinci; S Di Carlo; B Sensi; L Siragusa; A Guida; P Rossi; V Bellato; R Caronna; S Sibio Journal: Discov Oncol Date: 2021-08-06
Authors: Ji Hoon Park; Yoo-Seok Yoon; Seungjae Lee; Hae Young Kim; Ho-Seong Han; Jun Suh Lee; Won Chang; Haeryoung Kim; Hee Young Na; Seungyeob Han; Kyoung Ho Lee Journal: Korean J Radiol Date: 2022-01-06 Impact factor: 3.500